A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
NCT06144749
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
9
Enrollment
INDUSTRY
Sponsor class
Conditions
Anemia, Sickle Cell
Interventions
DRUG:
HBI-002
Sponsor
Hillhurst Biopharmaceuticals, Inc.
Collaborators
[object Object]